New Data Reinforces the Potential of CTx’s MOP Adjuvant Technology for Respiratory Vaccines

CTx and Boston Children’s Hospital have completed studies evaluating two proprietary mRNA MOP-based adjuvants in combination with a commercially available recombinant influenza vaccine (Flublok®, Sanofi) in adult and elderly mice.

These studies generated positive immunogenicity results, including microneutralization data, reinforcing the strong potential of our mRNA MOP-based adjuvants for next-generation respiratory disease vaccines.

Our MOP adjuvant technology has demonstrated the ability to enhance vaccine efficacy and extend the duration of protection, while supporting prime-only vaccination schedules — an important step toward improved pandemic preparedness.